Ping An Bio Pledges US$90M for Future Biotechnology Acquisition and Secures Strategic Investors
Ping An Biomedical Co. has signed a non-binding memorandum to invest US$30 million upfront and up to US$60 million in cash and share issuances to acquire Future Biotechnology Group. It also closed share purchase agreements with Yao Jinbo, Wang Donghui and Li Daxue, reinforcing capital backing for its AI-driven biopharmaceutical R&D and commercialisation expansion.
1. Investment Memorandum Details
Ping An Biomedical Co., Ltd (NASDAQ: PASW) has signed a non-binding memorandum with Future Biotechnology Group Co., Ltd outlining an initial US$30 million cash investment, followed by additional acquisitions totaling US$60 million in a mix of cash and share issuances. The agreement specifies that the Consideration Shares will be placed in escrow and released over a three-year evaluation period from January 2026 through December 2028 based on the target company’s audited revenue performance.
2. Performance-Based Consideration Shares
Release of one-fifth of the total Consideration Shares each year depends on meeting specific revenue thresholds: RMB 750 million for 2026, RMB 1.3 billion for 2027 and RMB 2.3 billion for 2028. Failure to meet targets results in cancelled shares according to a predefined formula, while outperformance by over 50% allows excess revenue to offset any prior shortfalls, creating a robust incentive mechanism tied directly to Future Biotechnology Group’s growth trajectory.
3. Strategic Rationale and Industry Impact
This strategic investment aligns with Ping An Bio’s “technology empowering healthcare” strategy, enabling deeper integration of biopharmaceutical R&D, clinical translation and industrial resources. By partnering with Future Biotechnology Group—an innovator in AI-driven drug discovery, genetic testing and medical devices—Ping An Bio positions itself to accelerate commercialization of novel therapies and strengthen its competitive edge in the fast-evolving biopharmaceutical sector.